A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours

A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours

Abstract Background We previously reported that low-dose, short-course sunitinib prior to neoadjuvant doxorubicin-cyclophosphamide (AC) normalised tumour vasculature and improved perfusion, but resulted in neutropenia and delayed subsequent cycles in breast cancer patients. This study combined sunit...

Full description

Bibliographic Details
Main Authors: Yvonne L. E. Ang, Gwo Fuang Ho, Ross A. Soo, Raghav Sundar, Sing Huang Tan, Wei Peng Yong, Samuel G. W. Ow, Joline S. J. Lim, Wan Qin Chong, Phyu Pyar Soe, Bee Choo Tai, Lingzhi Wang, Boon Cher Goh, Soo-Chin Lee
Format: Article
Language:English
Published: BMC 2020-11-01
Series:BMC Cancer
Subjects:
Tumour vasculature
Anti-angiogenic
Short-course sunitinib
Advanced solid tumours
Docetaxel
Online Access:http://link.springer.com/article/10.1186/s12885-020-07616-4

Internet

http://link.springer.com/article/10.1186/s12885-020-07616-4

Similar Items